[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations]

Zhonghua Nei Ke Za Zhi. 2016 Oct 1;55(10):794-796. doi: 10.3760/cma.j.issn.0578-1426.2016.10.014.
[Article in Chinese]

Abstract

To retrospectively analyze the efficacy of interferon plus imatinib (IM) in patients with chronic-phase chronic myelogenous leukemia(CML-CP)and ABL kinase domain mutations. The mutation rates of ABL kinase region in patients with Sokal score low, medium and high risk CML-CP were statistically significant (6.25%, 9.42% and 47.06%, P<0.05). The response rates of interferon plus IM versus second-generation TKI in CML-CP with non-T315I ABL kinase domain mutations were comparable (61.11% vs 65.52%, P>0.05). When CML-CP patients with ABL kinase domain mutations were resistant to TKI or not accessible to second-generation TKI, interferon plus IM can be an alternative choice.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate / administration & dosage*
  • Interferons / administration & dosage*
  • Interferons / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Mutation / drug effects*
  • Piperazines
  • Pyrimidines
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Interferons
  • Fusion Proteins, bcr-abl